Coloplast stock rises after 9M revenue update and guidance hold
Published on 08/20/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast A/S (DK0060448595) rose into the latest session after its 9M 2025/26 report showed 6% organic growth, EBIT of DKK 5.599 billion, and an unchanged FY 2025/26 outlook. The company said on August 18, 2026 that it still expects 5% to 6% organic revenue growth and about 5% EBIT growth in constant currencies.
What changed in 9M
The nine-month report covered October 1, 2025 to June 30, 2026, and it gave investors a clear read on the current year. Revenue rose 3% in reported Danish kroner, while net profit before special items increased DKK 510 million to DKK 4.289 billion.
Free cash flow conversion also strengthened, with free cash flow as a share of sales at 20% versus 16% a year earlier. Return on invested capital after tax before special items was 15%, which matched last year on an adjusted basis.
Targets stayed intact
The same report kept FY 2025/26 guidance unchanged, including 5% to 6% organic growth, about 5% EBIT growth in constant currencies, and about 15% return on invested capital after tax before special items. Reported revenue growth in Danish kroner is still expected at about 3%, helped by a neutral net currency effect in the quarter and a 2 to 3 percentage point headwind on the full-year top line.
That mix matters because Coloplast is still balancing solid demand in Chronic Care and Urology with pressure in Biologics, where the quarter showed a 6% decline in revenue and a negative 5% margin before PPA amortization.
Peer reaction
The MarketScreener news feed showed a Tradegate close of EUR 59.28, down 0.44% for the year and up 1.79% over five days as of August 19, 2026. In the same feed, Bernstein lifted its price target to DKK 455, Danske Bank to DKK 450, Handelsbanken to DKK 440, and Jefferies to DKK 625 after the fiscal third-quarter results.
That spread shows how the earnings update left room for different readings of Coloplast's path into the next quarter. The stock still trades with the Kerecis reset, but the current report also shows a company that held its organic growth and cash-flow targets.
Coloplast products
Coloplast's portfolio spans Ostomy Care, Continence Care, Voice and Respiratory Care, Wound and Tissue Repair, and Interventional Urology. In the quarter, Ostomy grew 5%, Continence 8%, Voice and Respiratory Care 6%, Wound and Tissue Repair 3%, and Urology 7%.
Stock close
The latest quoted Tradegate level was EUR 59.28 as of August 19, 2026, with the stock down 20.42% year to date. That leaves investors weighing a 6% organic-growth quarter against a still-sharp valuation reset.
Fact box
Company: Coloplast A/S
ISIN: DK0060448595
Ticker: CBHD
Exchange: Tradegate
Price (as of August 19, 2026): EUR 59.28
Market cap: DKK 214.0 billion
Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
Index membership: OMX Copenhagen 25
More on Coloplast stock
The current investment story centers on the 9M 2025/26 mix, where 6% organic growth, DKK 5.599 billion in EBIT, and a 20% free-cash-flow conversion rate frame the next leg of execution.
